Skip to main content
Top
Published in: BMC Infectious Diseases 1/2014

Open Access 01-12-2014 | Research article

Prevalence of hepatitis B and hepatitis C infection in Libya: results from a national population based survey

Authors: Mohamed A Daw, Abdallah El-Bouzedi, In association with Libyan Study Group of Hepatitis & HIV

Published in: BMC Infectious Diseases | Issue 1/2014

Login to get access

Abstract

Background

Libya is one of the largest countries in Africa and has the longest coast in the Mediterranean basin facing southern Europe. High rates of prevalence of viral hepatitis have been observed in various regions in Africa, but the prevalence in Libya is not well documented. We report on a large-scale nationwide study that evaluated the epidemiology of hepatitis B and hepatitis C in Libya and assessed the risk factors involved.

Methods

A cross-sectional study was carried out in 2008 on 65,761 individuals all over Libya. The country was divided into 12 regions according to the population density and sampling within each region was carried out under the supervision of the National Centre for Prevention of Infectious Diseases. Serum samples were collected from both males and females of all ages in both urban and rural areas and tested for HBsAg for hepatitis B and anti-HCV antibody for hepatitis C. Prevalence rates were determined in regions and in different groups and correlated with different demographic and risk factors involved in the spread of these viruses.

Results

The prevalence of hepatitis B and hepatitis C viruses varied regionally across the country. The overall prevalence of hepatitis B was 2.2% (95% CI 2.1%-2.3%) and was higher among males than females (1.4:1.0). Hepatitis C virus (HCV) prevalence was 1.2% (95% CI 1.1-1.3) and it increased gradually after the age of 30 years (0.7-0.9% for < 30 years; 3.6% for ≥ 60 years). Prevalence of HBsAg was 0.8-0.9% below the age of 10 years, and higher but similar in older age groups (2.3-2.7%). There was an association between literacy and prevalence of hepatitis, particularly for HCV. Hospital admission, surgical operation, blood transfusion, and intravenous drug use were the main risk factors, and they were associated independently with a higher prevalence rate of viral hepatitis.

Conclusions

Libya may be considered an area of low-intermediate endemicity for hepatitis B virus infection, with lower rates in young age groups, and an area of low endemicity for hepatitis C. The prevalence of hepatitis B and C across Libya is not homogeneous, with indications of the effect of the higher rates in some neighbouring countries. Libya should adopt full coverage national plans and guidelines to face the future consequences of viral hepatitis, particularly hepatitis C virus.
Appendix
Available only for authorised users
Literature
1.
go back to reference Te HS, Jensen DM: Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010, 14 (1): 1-21. 10.1016/j.cld.2009.11.009. viiCrossRefPubMed Te HS, Jensen DM: Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010, 14 (1): 1-21. 10.1016/j.cld.2009.11.009. viiCrossRefPubMed
2.
4.
go back to reference Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004, 11 (2): 97-107. 10.1046/j.1365-2893.2003.00487.x.CrossRefPubMed Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004, 11 (2): 97-107. 10.1046/j.1365-2893.2003.00487.x.CrossRefPubMed
5.
go back to reference Rey-Cuille MA, Seck A, Njouom R, Chartier L, Sow HD M, Ka AS, Njankouo M, Rousset D, Giles-Vernick T, et al: Low immune response to hepatitis B vaccine among children in Dakar, Senegal. PLoS One. 2012, 7 (5): e38153-10.1371/journal.pone.0038153.CrossRefPubMedPubMedCentral Rey-Cuille MA, Seck A, Njouom R, Chartier L, Sow HD M, Ka AS, Njankouo M, Rousset D, Giles-Vernick T, et al: Low immune response to hepatitis B vaccine among children in Dakar, Senegal. PLoS One. 2012, 7 (5): e38153-10.1371/journal.pone.0038153.CrossRefPubMedPubMedCentral
6.
go back to reference Abdel-Hady M, Kelly D: Chronic hepatitis B in children and adolescents: epidemiology and management. Paediatr Drugs. 2013, 15 (4): 311-317. 10.1007/s40272-013-0010-z.CrossRefPubMed Abdel-Hady M, Kelly D: Chronic hepatitis B in children and adolescents: epidemiology and management. Paediatr Drugs. 2013, 15 (4): 311-317. 10.1007/s40272-013-0010-z.CrossRefPubMed
7.
go back to reference Daw MA, Siala IM, Warfalli MM, Muftah MI: Seroepidemiology of hepatitis B virus markers among hospital health care workers. Analysis of certain potential risk factors. Saudi Med J. 2000, 21 (12): 1157-1160.PubMed Daw MA, Siala IM, Warfalli MM, Muftah MI: Seroepidemiology of hepatitis B virus markers among hospital health care workers. Analysis of certain potential risk factors. Saudi Med J. 2000, 21 (12): 1157-1160.PubMed
8.
go back to reference Jafari N, Farajzadegan Z, Ataei B: Surveillance system for hepatitis C infection: a practical approach. Int J Prev Med. 2012, 3 (Suppl 1): S48-57.PubMedPubMedCentral Jafari N, Farajzadegan Z, Ataei B: Surveillance system for hepatitis C infection: a practical approach. Int J Prev Med. 2012, 3 (Suppl 1): S48-57.PubMedPubMedCentral
9.
go back to reference Miller ER, McNally S, Wallace J, Schlichthorst M: The ongoing impacts of hepatitis c–a systematic narrative review of the literature. BMC Public Health. 2012, 12: 672-10.1186/1471-2458-12-672.CrossRefPubMedPubMedCentral Miller ER, McNally S, Wallace J, Schlichthorst M: The ongoing impacts of hepatitis c–a systematic narrative review of the literature. BMC Public Health. 2012, 12: 672-10.1186/1471-2458-12-672.CrossRefPubMedPubMedCentral
10.
go back to reference Muhlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U: HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health. 2009, 9: 34-10.1186/1471-2458-9-34.CrossRefPubMedPubMedCentral Muhlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U: HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health. 2009, 9: 34-10.1186/1471-2458-9-34.CrossRefPubMedPubMedCentral
11.
go back to reference WHO: Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 1999, 6 (1): 35-47.CrossRef WHO: Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 1999, 6 (1): 35-47.CrossRef
12.
go back to reference Abdelwahab SF, Hashem M, Galal I, Sobhy M, Abdel-Ghaffar TS, Galal G, Mikhail N, El-Kamary SS, Waked I, Strickland GT: Incidence of hepatitis C virus infection among Egyptian healthcare workers at high risk of infection. J Clin Virol. 2013, 57 (1): 24-28. 10.1016/j.jcv.2013.01.005.CrossRefPubMed Abdelwahab SF, Hashem M, Galal I, Sobhy M, Abdel-Ghaffar TS, Galal G, Mikhail N, El-Kamary SS, Waked I, Strickland GT: Incidence of hepatitis C virus infection among Egyptian healthcare workers at high risk of infection. J Clin Virol. 2013, 57 (1): 24-28. 10.1016/j.jcv.2013.01.005.CrossRefPubMed
13.
go back to reference Daw MA, Elkaber MA, Drah AM, Werfalli MM, Mihat AA, Siala IM: Prevalence of hepatitis C virus antibodies among different populations of relative and attributable risk. Saudi Med J. 2002, 23 (11): 1356-1360.PubMed Daw MA, Elkaber MA, Drah AM, Werfalli MM, Mihat AA, Siala IM: Prevalence of hepatitis C virus antibodies among different populations of relative and attributable risk. Saudi Med J. 2002, 23 (11): 1356-1360.PubMed
14.
go back to reference Elasifer HA, Agnnyia YM, Al-Alagi BA, Daw MA: Epidemiological manifestations of hepatitis C virus genotypes and its association with potential risk factors among Libyan patients. Virol J. 2010, 7: 317-10.1186/1743-422X-7-317.CrossRefPubMedPubMedCentral Elasifer HA, Agnnyia YM, Al-Alagi BA, Daw MA: Epidemiological manifestations of hepatitis C virus genotypes and its association with potential risk factors among Libyan patients. Virol J. 2010, 7: 317-10.1186/1743-422X-7-317.CrossRefPubMedPubMedCentral
15.
go back to reference Kershenobich D, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, Zuckerman E, Koike K, Han KH, Wallace CM, et al: Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. Liver Int. 2011, 31 (Suppl 2): 4-17.CrossRefPubMed Kershenobich D, Razavi HA, Cooper CL, Alberti A, Dusheiko GM, Pol S, Zuckerman E, Koike K, Han KH, Wallace CM, et al: Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. Liver Int. 2011, 31 (Suppl 2): 4-17.CrossRefPubMed
16.
go back to reference Remis R: Final Report. Community Acquired Infections Division, Centre for Communicable Diseases and Infection Control. Public Health Agency of Canada. 2009 Remis R: Final Report. Community Acquired Infections Division, Centre for Communicable Diseases and Infection Control. Public Health Agency of Canada. 2009
17.
go back to reference Daw MA, Dau AA, Agnan MM: Influence of healthcare-associated factors on the efficacy of hepatitis C therapy. Scientific World Journal. 2012, 2012: 580216-PubMedPubMedCentral Daw MA, Dau AA, Agnan MM: Influence of healthcare-associated factors on the efficacy of hepatitis C therapy. Scientific World Journal. 2012, 2012: 580216-PubMedPubMedCentral
18.
go back to reference Heisey-Grove DM, Church DR, Haney GA, Demaria A: Enhancing surveillance for hepatitis C through public health informatics. Public Health Rep. 2011, 126 (1): 13-18.PubMedPubMedCentral Heisey-Grove DM, Church DR, Haney GA, Demaria A: Enhancing surveillance for hepatitis C through public health informatics. Public Health Rep. 2011, 126 (1): 13-18.PubMedPubMedCentral
20.
go back to reference El Oakley RM, Ghrew MH, Aboutwerat AA, Alageli NA, Neami KA, Kerwat RM, Elfituri AA, Ziglam HM, Saifenasser AM, Bahron AM, et al: Consultation on the Libyan health systems: towards patient-centred services. Libyan J Med. 2013, 8: El Oakley RM, Ghrew MH, Aboutwerat AA, Alageli NA, Neami KA, Kerwat RM, Elfituri AA, Ziglam HM, Saifenasser AM, Bahron AM, et al: Consultation on the Libyan health systems: towards patient-centred services. Libyan J Med. 2013, 8:
22.
go back to reference El Taguri A, Elkhammas E, Bakoush O, Ashammakhi N, Baccoush M, Betilmal I: Libyan National Health Services The Need to Move to Management-by-Objectives. Libyan J Med. 2008, 3 (2): 113-121.CrossRefPubMedPubMedCentral El Taguri A, Elkhammas E, Bakoush O, Ashammakhi N, Baccoush M, Betilmal I: Libyan National Health Services The Need to Move to Management-by-Objectives. Libyan J Med. 2008, 3 (2): 113-121.CrossRefPubMedPubMedCentral
23.
26.
go back to reference Daw MA, Elwarvelli MM, Siala IM, Backush M, Elussabie H: Prevalence of HBsAg among Libyan populations: a comparative study. Annals of Saudi Medicine. 2001, 21: 130-132. Daw MA, Elwarvelli MM, Siala IM, Backush M, Elussabie H: Prevalence of HBsAg among Libyan populations: a comparative study. Annals of Saudi Medicine. 2001, 21: 130-132.
27.
go back to reference Alashek WA, Christopher W, McIntyre CW, Taal MW: Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infectious Diseases. 2012, 12: 265-10.1186/1471-2334-12-265. doi:10.1186/1471-2334-12-265CrossRefPubMedPubMedCentral Alashek WA, Christopher W, McIntyre CW, Taal MW: Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infectious Diseases. 2012, 12: 265-10.1186/1471-2334-12-265. doi:10.1186/1471-2334-12-265CrossRefPubMedPubMedCentral
28.
go back to reference Karatapanis S, Skorda L, Marinopoulos S, Papastergiou V, Drogosi M, Lisgos P, Antsaklis A: Higher rates of chronic hepatitis B infection and low vaccination-induced protection rates among parturients escaping HBsAg prenatal testing in Greece: a 2-year prospective study. Eur J Gastroenterol Hepatol. 2012, 24 (8): 878-883. 10.1097/MEG.0b013e328354834f.CrossRefPubMed Karatapanis S, Skorda L, Marinopoulos S, Papastergiou V, Drogosi M, Lisgos P, Antsaklis A: Higher rates of chronic hepatitis B infection and low vaccination-induced protection rates among parturients escaping HBsAg prenatal testing in Greece: a 2-year prospective study. Eur J Gastroenterol Hepatol. 2012, 24 (8): 878-883. 10.1097/MEG.0b013e328354834f.CrossRefPubMed
29.
go back to reference Romano L, Velati C, Cambie G, Fomiatti L, Galli C, Zanetti AR: Hepatitis B virus infection among first-time blood donors in Italy: prevalence and correlates between serological patterns and occult infection. Blood Transfus. 2013, 11 (2): 281-288.PubMedPubMedCentral Romano L, Velati C, Cambie G, Fomiatti L, Galli C, Zanetti AR: Hepatitis B virus infection among first-time blood donors in Italy: prevalence and correlates between serological patterns and occult infection. Blood Transfus. 2013, 11 (2): 281-288.PubMedPubMedCentral
30.
go back to reference Ezzikouri S, Pineau P, Benjelloun S: Hepatitis B virus in the Maghreb region: from epidemiology to prospective research. Liver Int. 2013, 33 (6): 811-819. 10.1111/liv.12135.CrossRefPubMed Ezzikouri S, Pineau P, Benjelloun S: Hepatitis B virus in the Maghreb region: from epidemiology to prospective research. Liver Int. 2013, 33 (6): 811-819. 10.1111/liv.12135.CrossRefPubMed
31.
go back to reference Barth RE, Huijgen Q, Taljaard J, Hoepelman AI: Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis. 2010, 14 (12): e1024-1031.CrossRefPubMed Barth RE, Huijgen Q, Taljaard J, Hoepelman AI: Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis. 2010, 14 (12): e1024-1031.CrossRefPubMed
32.
go back to reference Wasfi O, Sadek N: Prevalence of hepatitis B surface antigen and hepatitis C virus antibodies among blood donors in Alexandria. Egypt. East Mediterr Health J. 2011, 17 (3): 238-242.PubMed Wasfi O, Sadek N: Prevalence of hepatitis B surface antigen and hepatitis C virus antibodies among blood donors in Alexandria. Egypt. East Mediterr Health J. 2011, 17 (3): 238-242.PubMed
33.
go back to reference Goritsas C, Plerou I, Agaliotis S, Spinthaki R, Mimidis K, Velissaris D, Lazarou N, Labropoulou-Karatza C: HCV infection in the general population of a Greek island: prevalence and risk factors. Hepatogastroenterology. 2000, 47 (33): 782-785.PubMed Goritsas C, Plerou I, Agaliotis S, Spinthaki R, Mimidis K, Velissaris D, Lazarou N, Labropoulou-Karatza C: HCV infection in the general population of a Greek island: prevalence and risk factors. Hepatogastroenterology. 2000, 47 (33): 782-785.PubMed
34.
go back to reference Raffaele A, Valenti M, Iovenitti M, Matani A, Bruno ML, Altobelli E, D'Alessandro A, Barnabei R, Leonardis B, Taglieri G: High prevalence of HCV infection among the general population in a rural area of central Italy. Eur J Epidemiol. 2001, 17 (1): 41-46. 10.1023/A:1010932832190.CrossRefPubMed Raffaele A, Valenti M, Iovenitti M, Matani A, Bruno ML, Altobelli E, D'Alessandro A, Barnabei R, Leonardis B, Taglieri G: High prevalence of HCV infection among the general population in a rural area of central Italy. Eur J Epidemiol. 2001, 17 (1): 41-46. 10.1023/A:1010932832190.CrossRefPubMed
35.
go back to reference Benouda A, Boujdiya Z, Ahid S, Abouqal R, Adnaoui M: [Prevalence of hepatitis C virus infection in Morocco and serological tests assessment of detection for the viremia prediction]. Pathol Biol (Paris). 2009, 57 (5): 368-372. 10.1016/j.patbio.2008.07.006.CrossRef Benouda A, Boujdiya Z, Ahid S, Abouqal R, Adnaoui M: [Prevalence of hepatitis C virus infection in Morocco and serological tests assessment of detection for the viremia prediction]. Pathol Biol (Paris). 2009, 57 (5): 368-372. 10.1016/j.patbio.2008.07.006.CrossRef
36.
go back to reference Mejri S, Salah AB, Triki H, Alaya NB, Djebbi A, Dellagi K: Contrasting patterns of hepatitis C virus infection in two regions from Tunisia. J Med Virol. 2005, 76 (2): 185-193. 10.1002/jmv.20342.CrossRefPubMed Mejri S, Salah AB, Triki H, Alaya NB, Djebbi A, Dellagi K: Contrasting patterns of hepatitis C virus infection in two regions from Tunisia. J Med Virol. 2005, 76 (2): 185-193. 10.1002/jmv.20342.CrossRefPubMed
37.
go back to reference Cozzolongo R, Osella AR, Elba S, Petruzzi J, Buongiorno G, Giannuzzi V, Leone G, Bonfiglio C, Lanzilotta E, Manghisi OG, et al: Epidemiology of HCV infection in the general population: a survey in a southern Italian town. Am J Gastroenterol. 2009, 104 (11): 2740-2746. 10.1038/ajg.2009.428.CrossRefPubMed Cozzolongo R, Osella AR, Elba S, Petruzzi J, Buongiorno G, Giannuzzi V, Leone G, Bonfiglio C, Lanzilotta E, Manghisi OG, et al: Epidemiology of HCV infection in the general population: a survey in a southern Italian town. Am J Gastroenterol. 2009, 104 (11): 2740-2746. 10.1038/ajg.2009.428.CrossRefPubMed
38.
go back to reference Garcia-Fulgueiras A, Tormo MJ, Rodriguez T, Perez-Flores D, Chirlaque D, Navarro C: Prevalence of hepatitis B and C markers in the south-east of Spain: an unlinked community-based serosurvey of 2,203 adults. Scand J Infect Dis. 1996, 28 (1): 17-20. 10.3109/00365549609027143.CrossRefPubMed Garcia-Fulgueiras A, Tormo MJ, Rodriguez T, Perez-Flores D, Chirlaque D, Navarro C: Prevalence of hepatitis B and C markers in the south-east of Spain: an unlinked community-based serosurvey of 2,203 adults. Scand J Infect Dis. 1996, 28 (1): 17-20. 10.3109/00365549609027143.CrossRefPubMed
39.
go back to reference Gogos CA, Fouka KP, Nikiforidis G, Avgeridis K, Sakellaropoulos G, Bassaris H, Maniatis A, Skoutelis A: Prevalence of hepatitis B and C virus infection in the general population and selected groups in South-Western Greece. Eur J Epidemiol. 2003, 18 (6): 551-557.CrossRefPubMed Gogos CA, Fouka KP, Nikiforidis G, Avgeridis K, Sakellaropoulos G, Bassaris H, Maniatis A, Skoutelis A: Prevalence of hepatitis B and C virus infection in the general population and selected groups in South-Western Greece. Eur J Epidemiol. 2003, 18 (6): 551-557.CrossRefPubMed
40.
go back to reference Breban R, Doss W, Esmat G, Elsayed M, Hellard M, Ayscue P, Albert M, Fontanet A, Mohamed MK: Towards realistic estimates of HCV incidence in Egypt. J Viral Hepat. 2013, 20 (4): 294-296. 10.1111/j.1365-2893.2012.01650.x.CrossRefPubMed Breban R, Doss W, Esmat G, Elsayed M, Hellard M, Ayscue P, Albert M, Fontanet A, Mohamed MK: Towards realistic estimates of HCV incidence in Egypt. J Viral Hepat. 2013, 20 (4): 294-296. 10.1111/j.1365-2893.2012.01650.x.CrossRefPubMed
41.
go back to reference Guerra J, Garenne M, Mohamed MK, Fontanet A: HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat. 2012, 19 (8): 560-567. 10.1111/j.1365-2893.2011.01576.x.CrossRefPubMed Guerra J, Garenne M, Mohamed MK, Fontanet A: HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat. 2012, 19 (8): 560-567. 10.1111/j.1365-2893.2011.01576.x.CrossRefPubMed
42.
go back to reference Triki H, Said N, Ben Salah A, Arrouji A, Ben Ahmed F, Bouguerra A, Hmida S, Dhahri R, Dellagi K: Seroepidemiology of hepatitis B, C and delta viruses in Tunisia. Trans R Soc Trop Med Hyg. 1997, 91 (1): 11-14. 10.1016/S0035-9203(97)90374-6.CrossRefPubMed Triki H, Said N, Ben Salah A, Arrouji A, Ben Ahmed F, Bouguerra A, Hmida S, Dhahri R, Dellagi K: Seroepidemiology of hepatitis B, C and delta viruses in Tunisia. Trans R Soc Trop Med Hyg. 1997, 91 (1): 11-14. 10.1016/S0035-9203(97)90374-6.CrossRefPubMed
43.
44.
go back to reference Uhanova J, Tate RB, Tataryn DJ, Minuk GY: A population-based study of the epidemiology of hepatitis C in a North American population. J Hepatol. 2012, 57 (4): 736-742. 10.1016/j.jhep.2012.05.018.CrossRefPubMed Uhanova J, Tate RB, Tataryn DJ, Minuk GY: A population-based study of the epidemiology of hepatitis C in a North American population. J Hepatol. 2012, 57 (4): 736-742. 10.1016/j.jhep.2012.05.018.CrossRefPubMed
45.
go back to reference Havens JR, Lofwall MR, Frost SD, Oser CB, Leukefeld CG, Crosby RA: Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health. 2012, 103 (1): e44-52.CrossRefPubMed Havens JR, Lofwall MR, Frost SD, Oser CB, Leukefeld CG, Crosby RA: Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health. 2012, 103 (1): e44-52.CrossRefPubMed
46.
go back to reference Wong NS, Chan PC, Lee SS, Lee SL, Lee CK: A multilevel approach for assessing the variability of hepatitis C prevalence in injection drug users by their gathering places. Int J Infect Dis. 2013, 17 (3): e193-198. 10.1016/j.ijid.2012.10.004.CrossRefPubMed Wong NS, Chan PC, Lee SS, Lee SL, Lee CK: A multilevel approach for assessing the variability of hepatitis C prevalence in injection drug users by their gathering places. Int J Infect Dis. 2013, 17 (3): e193-198. 10.1016/j.ijid.2012.10.004.CrossRefPubMed
47.
go back to reference McDonald SA, Hutchinson SJ, Schnier C, McLeod A, Goldberg DJ: Estimating the number of injecting drug users in Scotland's HCV-diagnosed population using capture-recapture methods. Epidemiol Infect. 2014, 142 (1): 200-207.PubMed McDonald SA, Hutchinson SJ, Schnier C, McLeod A, Goldberg DJ: Estimating the number of injecting drug users in Scotland's HCV-diagnosed population using capture-recapture methods. Epidemiol Infect. 2014, 142 (1): 200-207.PubMed
48.
go back to reference Sood A, Sarin SK, Midha V, Hissar S, Sood N, Bansal P, Bansal M: Prevalence of hepatitis C virus in a selected geographical area of northern India: a population based survey. Indian J Gastroenterol. 2012, 31 (5): 232-236. 10.1007/s12664-012-0251-8.CrossRefPubMed Sood A, Sarin SK, Midha V, Hissar S, Sood N, Bansal P, Bansal M: Prevalence of hepatitis C virus in a selected geographical area of northern India: a population based survey. Indian J Gastroenterol. 2012, 31 (5): 232-236. 10.1007/s12664-012-0251-8.CrossRefPubMed
49.
go back to reference Szabo SM, Bibby M, Yuan Y, Donato BM, Jimenez-Mendez R, Castaneda-Hernandez G, Rodriguez-Torres M, Levy AR: The epidemiologic burden of hepatitis C virus infection in Latin America. Ann Hepatol. 2012, 11 (5): 623-635.PubMed Szabo SM, Bibby M, Yuan Y, Donato BM, Jimenez-Mendez R, Castaneda-Hernandez G, Rodriguez-Torres M, Levy AR: The epidemiologic burden of hepatitis C virus infection in Latin America. Ann Hepatol. 2012, 11 (5): 623-635.PubMed
51.
go back to reference El-Bouzedi A: Investigation and modeling the epidemiology of hepatitis C virus in Libya, Ph D Thesis. 2012, United Kingdom: University of Glamorgan, Faculty of Advanced Technology El-Bouzedi A: Investigation and modeling the epidemiology of hepatitis C virus in Libya, Ph D Thesis. 2012, United Kingdom: University of Glamorgan, Faculty of Advanced Technology
Metadata
Title
Prevalence of hepatitis B and hepatitis C infection in Libya: results from a national population based survey
Authors
Mohamed A Daw
Abdallah El-Bouzedi
In association with Libyan Study Group of Hepatitis & HIV
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2014
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-14-17

Other articles of this Issue 1/2014

BMC Infectious Diseases 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.